New Schizophrenia Drug Shows Promise In Phase II Human Trials
A new experimental drug for the treatment of schizophrenia which targets glutamate receptors in the brain rather than dopamine has shown promise in human trials. The volunteers experienced significant improvements in their symptoms while suffering few side effects. The drug is currently called “LY2140023″.You can read about this trial in an article published in Nature Medicine.
